In patients with rheumatic heart disease-associated atrial fibrillation, vitamin K antagonist therapy was associated with a lower rate of ischemic stroke and mortality compared with rivaroxaban, without increasing risk for major bleeding.“Vitamin K antagonists should remain the standard of care for rheumatic heart disease-associated atrial fibrillation,” Ganesan Karthikeyan, MD, DM,
/PRNewswire/ CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using.
/PRNewswire/ CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using.
Study supports early discharge, ambulatory rivaroxaban in low-risk pulmonary embolism healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.